Should this be the case, the analysis of the phosphorylation levels of mTORC1 and -2 protein targets in patients’ biopsies, along with the definition of the immune cell infiltrate would represent a feasible methodology for orienting the choice of the most appropriate first-line treatment between ICI and targeted therapy in patients bearing BRAF-mutated melanomas. The gene discussed is BRAF; the disease is melanoma.